Edwards Lifesciences Corporation $EW Shares Sold by Fideuram Intesa Sanpaolo Private Banking S.P.A.

Fideuram Intesa Sanpaolo Private Banking S.P.A. trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 41.0% during the first quarter, HoldingsChannel.com reports. The firm owned 11,247 shares of the medical research company’s stock after selling 7,826 shares during the quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Edwards Lifesciences were worth $901,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of EW. Boston Trust Walden Corp increased its position in Edwards Lifesciences by 6.0% during the 1st quarter. Boston Trust Walden Corp now owns 282,950 shares of the medical research company’s stock worth $22,659,000 after purchasing an additional 16,045 shares in the last quarter. Keybank National Association OH raised its holdings in Edwards Lifesciences by 14.2% in the first quarter. Keybank National Association OH now owns 38,717 shares of the medical research company’s stock valued at $3,100,000 after buying an additional 4,809 shares during the period. Root Financial Partners LLC lifted its position in Edwards Lifesciences by 53.0% during the first quarter. Root Financial Partners LLC now owns 1,137 shares of the medical research company’s stock valued at $91,000 after buying an additional 394 shares in the last quarter. Financial Life Planners acquired a new position in Edwards Lifesciences during the first quarter valued at approximately $96,000. Finally, USS Investment Management Ltd lifted its position in Edwards Lifesciences by 8.1% during the first quarter. USS Investment Management Ltd now owns 126,927 shares of the medical research company’s stock valued at $10,165,000 after buying an additional 9,504 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 58,977 shares of company stock valued at $4,921,803 over the last ninety days. 0.31% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

EW has been the subject of several recent research reports. TD Cowen reissued a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Wednesday, April 1st. Robert W. Baird upped their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Mizuho set a $95.00 price target on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Monday, April 13th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $96.39.

Edwards Lifesciences Trading Down 0.1%

NYSE EW opened at $94.31 on Friday. The company has a market capitalization of $54.31 billion, a price-to-earnings ratio of 50.17, a price-to-earnings-growth ratio of 2.37 and a beta of 0.86. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $94.47. The company’s fifty day moving average price is $85.61 and its two-hundred day moving average price is $83.57.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.